Ultram er patent biovail

Biovail NDA For Ralivia ER -- Tramadol Extended Release Tablets -- Accepted for Review. In the United States, the patent for Ultracet expires in August 2011.

Biovail NDA For Ralivia ER -- Tramadol Extended Release Tablets.

Biovail’s current drug portfolio will face another series of patent expirations in 2014 and 2015. In FY2014, Biovail will lose patent protection on Ultram ER, which.

... and Purdue provides patent protection through 2014 for Biovail's formulation, which may extend the branded market opportunity for Ultram(R) ER. Biovail has two patents.
Biovail Enters Into Commercial Alliance for Tramadol Products.
FOR THE DISTRICT OF DELAWARE PURDUE PHARMA PRODUCTS L.P., NAPP.

Stock:Biovail (TSE:BVF) - See your portfolio in a whole new light.

In compliance with 21 U.S.C. § 355(b)(1), Biovail certified to the FDA that the ‘887 and ‘430 patent claims cover Ultram® ER. PADDOCK’S ANDA

Ultram er patent biovail Johnson-And-Johnson - 0066

2005 Annual Report - BIOVAIL CORP INTERNATIONAL - 5-30-2006 v. Biovail Reports Fourth Quarter, Year-End 2009 Financial Results. Biovail Reports Fourth Quarter, Year-End 2009 Financial Results. SEC Info - Valeant Pharmaceuticals International/Inc - 6-K - For 3. Johnson-And-Johnson - 0066 .